Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



Efficacy Against RGE

ROTARIX demonstrated efficacy vs placebo in the prevention of rotavirus gastroenteritis (RGE)1

ROTARIX Demonstrated Significant Efficacy in the Prevention of RGE of Any Severity1,2

In a clinical trial studying the prevention of RGE, ROTARIX demonstrated:

87% efficacy in the prevention of RGE of any severity1,2


Primary efficacy endpoint from 2 weeks after the second dose through 1 rotavirus season (95% CI: 80, 92) (P<0.001 vs placebo; according to protocol [ATP])

90% first-dose efficacy in the prevention of RGE of any severity1


Secondary efficacy endpoint immediately following dose 1 and prior to dose 2 (95% CI: 9, 100) (total vaccinated cohort)

100% efficacy in reducing hospitalizations for RGE1


Secondary efficacy endpoint through 1 rotavirus season (95% CI: 82, 100) (P<0.001; ATP)

Study design:
A randomized, double-blind, placebo-controlled study was conducted in 6 European countries comparing ROTARIX (n=2572) vs placebo (n=1302). The first dose was given at 6-14 weeks of age, and the second dose was given at least 4 weeks after the first dose. The 2-dose series was completed by 24 weeks of age. Analysis of the ATP cohort included all infants in the efficacy cohort who received 2 doses of vaccine according to randomization.1,2


  1. Prescribing Information for ROTARIX.
  2. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370:1757-1763.
  3. Centers for Disease Control and Prevention. Recommended Immunization Schedules for Persons Aged 0 Through 18 Years—United States, 2016. http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed November 26, 2019.


ROTARIX is a vaccine indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series. ROTARIX is approved for use in infants 6 weeks to 24 weeks of age.

Important Safety Information

  • Contraindications for ROTARIX include a history of any of the following: hypersensitivity to the vaccine or any component of the vaccine, intussusception, uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception, or Severe Combined Immunodeficiency Disease (SCID)
  • The tip caps of the prefilled oral applicators of diluent contain natural rubber latex, which may cause allergic reactions
  • Administration in infants suffering from acute diarrhea or vomiting should be delayed. Safety and effectiveness in infants with chronic gastrointestinal disorders have not been evaluated
  • Safety and effectiveness in infants with known primary or secondary immunodeficiencies have not been established
  • A study conducted after approval of ROTARIX showed an increased risk of intussusception in the 31 days after the first dose of ROTARIX, especially in the first 7 days. In other reports, an increased risk of intussusception has been observed within 7 days after dose 2
  • In clinical studies, common adverse reactions in infants receiving ROTARIX included fussiness/irritability, cough/runny nose, fever, loss of appetite, and vomiting
  • Vaccination with ROTARIX may not result in protection in all vaccine recipients

Please see full Prescribing Information for ROTARIX.